Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models

Zhou, Runhong; Wang, Pui; Wong, Yum-Shing; Xu, Haoran; Lau, Siu-Ying; Liu, Li; Mok, Bobo Wing-Yee; Peng, Qingsheng; Liu, Na; Woo, Kin-Fai; Deng, Shumin; Tam, Rachel Chun-Yee; Huang, Haode; Zhang, Anna Jinxia; Zhou, Dongyan; Zhou, Biao; Chan, Chun‐Yin; Du, Zhenglong; Yang, Dawei; Au, Ka‐Kit; Yuen, Kwok‐Yung; Chen, Honglin; Chen, Zhiwei

doi:10.1016/j.ebiom.2021.103762

Cited by 40 publications

(35 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HEK293T (RRID: CVCL_0063) and HEK293T-hACE2 (in-house made) (mycoplasma negative) were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher Scientific) containing 10% fetal bovine serum, 2 mM L-glutamine and 100 U/mL penicillin and were incubated at 37°C in 5% CO2 setting. 15,16 High-level and stable expression of human ACE2 on HEK293T-hACE2 cell line surface was validated by flow cytometry analysis.…”

Section: Cell Linesmentioning

confidence: 99%

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong

et al. 2022

Self Cite

View full text Add to dashboard Cite

Section: Cell Linesmentioning

confidence: 99%

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…An adenovirus type 5-vectored vaccine encoding RBD (AdCOVID) was found to induce RBD-specific IgA in the respiratory tract and sera of i.n. vaccinated mice ( 40 , 41 ). Although effective in protecting mice from a lethal SARS-CoV-2 challenge, development of AdCOVID by Altimmune has been discontinued due to lower than expected immune responses in a Phase I trial.…”

Section: Discussionmentioning

confidence: 99%

Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2

et al. 2022

View full text Add to dashboard Cite

Despite the remarkable efficacy of currently approved COVID-19 vaccines, there are several opportunities for continued vaccine development against SARS-CoV-2 and future lethal respiratory viruses. In particular, restricted vaccine access and hesitancy have limited immunization rates. In addition, current vaccines are unable to prevent breakthrough infections, leading to prolonged virus circulation. To improve access, a subunit vaccine with enhanced thermostability was designed to eliminate the need for an ultra-cold chain. The exclusion of infectious and genetic materials from this vaccine may also help reduce vaccine hesitancy. In an effort to prevent breakthrough infections, intranasal immunization to induce mucosal immunity was explored. A prototype vaccine comprised of receptor-binding domain (RBD) polypeptides formulated with additional immunoadjuvants in a chitosan (CS) solution induced high levels of RBD-specific antibodies in laboratory mice after 1 or 2 immunizations. Antibody responses were durable with high titers persisting for at least five months following subcutaneous vaccination. Serum anti-RBD antibodies contained both IgG1 and IgG2a isotypes suggesting that the vaccine induced a mixed Th1/Th2 response. RBD vaccination without CS formulation resulted in minimal anti-RBD responses. The addition of CpG oligonucleotides to the CS plus RBD vaccine formulation increased antibody titers more effectively than interleukin-12 (IL-12). Importantly, generated antibodies were cross-reactive against RBD mutants associated with SARS-CoV-2 variants of concern, including alpha, beta and delta variants, and inhibited binding of RBD to its cognate receptor angiotensin converting enzyme 2 (ACE2). With respect to stability, vaccines did not lose activity when stored at either room temperature (21-22°C) or 4°C for at least one month. When delivered intranasally, vaccines induced RBD-specific mucosal IgA antibodies, which may protect against breakthrough infections in the upper respiratory tract. Altogether, data indicate that the designed vaccine platform is versatile, adaptable and capable of overcoming key constraints of current COVID-19 vaccines.

show abstract

“…Ponownie jednak wybrano bezpieczeństwo [56]. Badania nad szczepionkami donosowymi nadal trwają [57].…”

Section: Niepożądane Odczyny Poszczepienne W Trakcie Badań Klinicznyc...unclassified

Adverse effects of vaccinations and potential therapies against COVID-19

Wasiak¹,

Rieske²

2022

pja

View full text Add to dashboard Cite

StrESzczEnIEW artykule przedstawiono, że terapie przeciwwirusowe są zdecydowanie bardziej szkodliwe oraz mniej skuteczne i dostępne niż szczepienia. Terapie przeciwwirusowe nie są skuteczne w zasadzie w II i III fazie choroby. Stosowanie terapii przeciwwirusowych u wszystkich pacjentów spowodowałoby wystąpienie u nich licznych działań niepożądanych, a tylko 10% chorych przechodzi z I do II fazy i wymaga takiego leczenia. Szansa na wyleczenie pacjentów z COVID-19 w II i III fazie choroby gwałtownie się zmniejsza. Szczepienia są natomiast bardzo skuteczne. Niepożądane odczyny poszczepienne występują rzadko; trwają intensywne badania zmierzające do wyjaśnienia ich etiopatogenezy. Z biotechnologicznego punktu widzenia szczepienia prowadzą do wytworzenia immunoterapii zbliżonej do CAR-T czy przeciwciał monoklonalnych, które działają od pierwszego dnia infekcji, a nie pierwszego dnia wystąpienia objawów, kiedy pacjenci mogą rozpocząć jakąś terapię. W przypadku COVID-19 stwierdzono zdecydowaną przewagę szczepienia nad terapią farmakologiczną. Ponieważ nie u wszystkich pacjentów szczepienie może być skuteczne, badania nad terapią powinny być intensywnie prowadzone. Prawidłowa farmakoterapia zależy od szybkiej współpracy diagnostów z lekarzami, a także od opracowania testów umożliwiających dobrać terapię i stwierdzenie, u kogo choroba, taka jak COVID-19, przejdzie z I fazy w II fazę. Zaszczepieni pacjenci zareagują najprawdopodobniej lepiej na stosowane terapie. Słowa kluczowE SARS-CoV-2, COVID-19, szczepionka, niepożądany odczyn poszczepienny (NOP), wzmocnienie zależne od przeciwciał (ADE).

show abstract

Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models

Cited by 40 publications

References 58 publications

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong

Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2

Adverse effects of vaccinations and potential therapies against COVID-19

Contact Info

Product

Resources

About